NCT07517224Not yet recruiting
Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to assess the feasibility of an 8-week aerobic exercise program and its effect on arterial function in breast cancer survivors. The main questions it aims to answer are: * Is an 8-week aerobic exercise program feasible in breast cancer survivors after the completion of chemotherapy, immunotherapy and/or anti-HER2 agents? * Is this 8-week aerobic exercise program beneficial for vascular function in breast cancer survivors? Participants will: * Begin an 8-week aerobic exercise program, three days per week, after the completion of chemotherapy, immunotherapy and/or anti-HER2 agents. * Visit our facility three times: before the exercise program, 1 month after, and after the completion of the program. * Complete questionnaires, physical functional tests, and body composition and vascular measurements at every visit.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 27 Mar 2026
- Start date
- Oct 2026
- Primary completion date
- May 2031
- Lead sponsor
- Loyola University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07517224
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Oct 2026 to the primary completion date, May 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current pregnant and lactating patients. Must have completed lactation prior to study start.
Other illness
- Metastatic disease.
Lab values
- Diagnosed cardiovascular disease prior to the initiation of cancer therapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.
Other
- Non-English speaking
Who the study is looking for
- Women (18-70 years) with a stage I-III breast cancer diagnosis who have completed chemotherapy, immunotherapy and/or anti-HER2 agents.
- Able to begin aerobic exercise within 12 weeks of the final chemotherapy, immunotherapy and/or anti-HER2 agents.
- Sedentary by self-reporting inactivity (\<90 min of moderate or vigorous exercise per week)
- Weight ≤154 kg
- Willing to complete all study activities
- Able to safely participate in moderate aerobic exercise.
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.